Literature DB >> 6100428

Transposon-mediated multiple antibiotic resistance in Acinetobacter strains.

M Devaud, F H Kayser, B Bächi.   

Abstract

Acinetobacter calcoaceticus subsp. anitratus, which is unusually resistant to multiple antibiotics, was the cause of an epidemic of respiratory tract infections in patients in an intensive care unit. A representative isolate of the epidemic strain was found to contain the aminoglycoside-modifying enzymes 3-N-acetyltransferase, 3'-phosphotransferase, and 3"-adenylyltransferase, which confer resistance to gentamicin, kanamycin, and streptomycin, respectively. In addition, the strain produced a cephalosporinase and was resistant to penicillins due to the production of a TEM-2 beta-lactamase. The bacterial isolate also exhibited resistance to chloramphenicol, tetracycline, and sulfonamides. The resistant phenotype of this strain was similar to resistance patterns frequently observed in endemic hospital flora, suggesting that the transfer of an R plasmid into Acinetobacter sp. may have occurred. However, antibiotic resistance could not be transferred to any recipient by various mating procedures. After plasmid RP4 was transferred into an ampicillin- and kanamycin-susceptible derivative of the epidemic strain, mobilization of resistance to chloramphenicol, gentamicin, streptomycin, sulfonamides, and possibly tetracycline could be achieved. This mobilization was due to the transposition of a 16-megadalton DNA sequence from the Acinetobacter chromosome into plasmid RP4. Insertion of the transposable sequence occurred near the PstI and SmaI sites around position 22.5 on the physical map of plasmid RP4. We suggest that a plasmid resistant to multiple antibiotics was transferred from the hospital flora into Acinetobacter sp. but could not be maintained stably in this host. Instead, a multiply resistant DNA sequence was transposed and stably integrated into the Acinetobacter chromosome. The occurrence of such multiply resistant transposons on conjugative plasmids contributes greatly to the genetic variability of bacteria and may sometimes have serious epidemiological and therapeutic consequences.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6100428      PMCID: PMC183733          DOI: 10.1128/AAC.22.2.323

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Host range and properties of the Pseudomonas aeruginosa R factor R1822.

Authors:  R H Olsen; P Shipley
Journal:  J Bacteriol       Date:  1973-02       Impact factor: 3.490

2.  Aminoglycoside antibiotics: inactivation by phosphorylation in Escherichia coli carrying R factors.

Authors:  B Ozanne; R Benveniste; D Tipper; J Davies
Journal:  J Bacteriol       Date:  1969-11       Impact factor: 3.490

3.  Elimination by ethidium bromide of antibiotic resistance in enterobacteria and staphylococci.

Authors:  D H Bouanchaud; M R Scavizzi; Y A Chabbert
Journal:  J Gen Microbiol       Date:  1968-12

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Complex mitochondrial DNA.

Authors:  B Hudson; D A Clayton; J Vinograd
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1968

6.  Supercoiled circular DNA-protein complex in Escherichia coli: purification and induced conversion to an opern circular DNA form.

Authors:  D B Clewell; D R Helinski
Journal:  Proc Natl Acad Sci U S A       Date:  1969-04       Impact factor: 11.205

7.  A comparative study of eight distinct beta-lactamases synthesized by gram-negative bacteria.

Authors:  G W Jack; M H Richmond
Journal:  J Gen Microbiol       Date:  1970-04

8.  Thymidine and thymine incorporation into deoxyribonucleic acid: inhibition and repression by uridine of thymidine phosphorylase of Escherichia coli.

Authors:  D R Budman; A B Pardee
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

9.  Properties of an R factor from Pseudomonas aeruginosa.

Authors:  N Datta; R W Hedges; E J Shaw; R B Sykes; M H Richmond
Journal:  J Bacteriol       Date:  1971-12       Impact factor: 3.490

10.  Genetic transformation in Escherichia coli K12.

Authors:  S D Cosloy; M Oishi
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

View more
  17 in total

1.  Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454.

Authors:  S Magnet; P Courvalin; T Lambert
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 2.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

3.  Dissemination of amikacin resistance gene aphA6 in Acinetobacter spp.

Authors:  T Lambert; G Gerbaud; P Bouvet; J F Vieu; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain.

Authors:  J Vila; J Ruiz; M Navia; B Becerril; I Garcia; S Perea; I Lopez-Hernandez; I Alamo; F Ballester; A M Planes; J Martinez-Beltran; T J de Anta
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  New aminoglycoside-modifying enzymes APH(3')-VIII and APH(3')-IX in Acinetobacter rudis and Acinetobacter gerneri.

Authors:  Eun-Jeong Yoon; Catherine Grillot-Courvalin; Patrice Courvalin
Journal:  J Antibiot (Tokyo)       Date:  2016-12-14       Impact factor: 2.649

9.  Origin in Acinetobacter gyllenbergii and dissemination of aminoglycoside-modifying enzyme AAC(6')-Ih.

Authors:  Eun-Jeong Yoon; Sylvie Goussard; Alexandr Nemec; Thierry Lambert; Patrice Courvalin; Catherine Grillot-Courvalin
Journal:  J Antimicrob Chemother       Date:  2015-12-07       Impact factor: 5.790

10.  Transferable amikacin resistance in Acinetobacter spp. due to a new type of 3'-aminoglycoside phosphotransferase.

Authors:  T Lambert; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.